THERANOTICS CO.,LTD. - search results

Canada - English - Health Canada

aybintio solution

samsung bioepis co., ltd - bevacizumab - solution - 100mg - bevacizumab 100mg

Canada - English - Health Canada

aybintio solution

samsung bioepis co., ltd - bevacizumab - solution - 400mg - bevacizumab 400mg

Israel - English - Ministry of Health

avastin

roche pharmaceuticals (israel) ltd - bevacizumab - concentrate for solution for infusion - bevacizumab 25 mg/ml - bevacizumab - bevacizumab - - avastin in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.- avastin in addition to platinum - based chemotherapy is indicated for first - line treatment of patients with unresectable advanced metastatic or recurrent non- small cell lung cancer other than predominantly squamous cell histology. - avastin in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and /or metastatic renal cell cancer. - avastin in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer.- avastin as asingle agent, is indicated for the treatment of glioblastoma in patients with progressive disease following prior therapy.- avastin, in combination with carboplatin and paclitaxel, is indicated for the front-line treatment of advanced (figo stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are at high risk for recurrence (residual disease after debulking).- avastin, in combination with carboplatin and gemcitabine, is indicated for the treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor-targeted agents.- avastin ( bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents - avastin ( bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan is indicated for treatment of patients with persistent, recurrent, or metastatic carcinoma of the cervix.- bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. - bevacizumab, in combination with atezolizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (hcc) who have not received prior systemic therapy.

Singapore - English - HSA (Health Sciences Authority)

vancomycin hcl injection 500 mgvial

zyfas pharma pte ltd - vancomycin hcl eqv vancomycin - injection, powder, for solution - vancomycin hcl eqv vancomycin 500 mg/vial

Australia - English - Department of Health (Therapeutic Goods Administration)

hexvix hexaminolevulinate (as hydrochloride) 85 mg powder for intravesical solution vial plus diluent vial

endotherapeutics pty ltd - hexaminolevulinate hydrochloride, quantity: 100 mg (equivalent: hexaminolevulinate, qty 85 mg) - diluent, not applicable - excipient ingredients: sodium hydroxide; dibasic sodium phosphate dihydrate; monobasic potassium phosphate; sodium chloride; water for injections; hydrochloric acid - this medicinal product is for diagnostic use only.,hexvix blue light fluorescence cystoscopy is indicated as adjunct to standard white light cystoscopy to contribute to the diagnosis and management of bladder cancer in patients with known or high suspicion of bladder cancer.